Dr. Fauci Looks Ahead to IAS Conference on HIV Science

Content From: HIV.govPublished: July 23, 20172 min read

Topics

The International AIDS Society Conference on HIV ScienceExit Disclaimer (IAS 2017) got underway in Paris on Sunday. As it began, Dr. Anthony Fauci, Director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), shared some thoughts on how research has impacted the course of the epidemic and the state of HIV research today. He spoke with his colleague and HIV.gov’s special correspondent Anne Rancourt in a Facebook Live event. View their conversation below or on the HIV.gov Facebook page

In setting the scene for the biennial conference, Dr. Fauci reflected on where we are today with scientific tools available to end the epidemic, including antiretroviral treatment that can suppress the virus to undetectable levels in people living with HIV and pre-exposure prophylaxis (PrEP) that can prevent acquisition of the virus for those who are HIV-negative, as well as promising ongoing areas of research that will be discussed at the conference, such as the current HIV vaccine trials. He and Anne also discussed the powerful role that treatment as prevention plays in efforts to end the epidemic. Finally, Dr. Fauci also previewed his featured presentation on Monday, Sustained ART-free HIV Remission: Opportunities and ObstaclesExit Disclaimer.

Tomorrow and Tuesday, NIAID’s Dr. Carl Dieffenbach will join Anne to share highlights of some of each day’s important new HIV research presentations. So be sure to tune in to the HIV.gov Facebook page at 1:00 PM (ET) to catch their updates.

The 9th IAS Conference on HIV Science is the largest open scientific conference on HIV and AIDS related issues—bringing together a broad cross-section of more than 6,000 professionals from around the world to meet and examine the latest scientific developments in HIV-related research with a focus on moving science into practice and policy. The conference is organized by the International AIDS SocietyExit Disclaimer (IAS) in partnership with ANRSExit Disclaimer (the French national agency for research on AIDS and viral hepatitis). For more information on the conference, visit www.ias2017.orgExit Disclaimer.